Influenza Vaccines and Febrile Seizures (PRISM)

Project Title Influenza Vaccines and Febrile Seizures (PRISM)
Date Posted
Friday, September 18, 2015
Status
Complete
Deliverables
Related Links
Description

Protocol-based assessment of the risk of febrile seizures following trivalent inactivated influenza vaccine administered during the 2010-11 influenza season among children ages 6 months through 59 months using a self-controlled risk interval design. Influenza vaccinations and febrile seizure cases were identified in electronic healthcare databases and underwent medical record review. The positive predictive value of three alternative febrile seizures definitions that use ICD9 data was evaluated. 

The information contained in this report is associated with an FDA Safety Communication issued on May 16, 2014. Click here to see the Safety Communication.

This protocol was posted for public comment from January 24, 2013 through February 7, 2013. A revised version was approved for implementation by FDA on April 26, 2013. A log of changes is included in the revised protocol (v2.0).

Medical Product
influenza vaccine
Health Outcome
febrile seizure
Population / Cohort
All children 6 - 59 months of age
Time Period
2010 - 2011
Assessment Type
Safety Analyses
Study Type
Protocol/Surveillance Plan
Workgroup Leader(s)

Alison Kawai ScD; Grace Lee MD, MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

Workgroup Members

Martin Kulldorff PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

David Martin MD, MPH; Center for Biologics Evaluation and Research, FDA, Silver Spring, MD

Cheryl McMahill-Walraven PhD, MSW; Aetna: Aetna Informatics, Blue Bell, PA

Mano Selvan PhD, Comprehensive Health Insights, Humana, Louisville, KY

Nandini Selvam PhD, MPH; HealthCore, Inc., Alexandria, VA

Data Sources
Mini-Sentinel Distributed Database (MSDD) and immunization registries in Florida, Michigan, Minnesota, New York City, New York State, Pennsylvania, Virginia, and Wisconsin
FDA Center
CBER